Image from Northern California Chapters: Momentum Building in Type 1 Diabetes Research and Advocacy as New Year Begins

Northern California Chapters (via breakthrought1d.org) / Source publication — credited and linked

Living With T1D/January 13, 2026/2 min read

Momentum Building in Type 1 Diabetes Research and Advocacy as New Year Begins

The Type 1 diabetes community is marking 2025's progress in cell therapy and disease-modifying treatments while rallying support for federal research funding set to expire this month.

News report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

living with t1dtechnologysupport

Key takeaways

Cell therapy and disease-modifying advances made meaningful progress in 2025, offering new directions for Type 1 diabetes treatment
The Special Diabetes Program, which has funded T1D research since 1997, faces a funding deadline of January 30, 2026, requiring community advocacy for renewal
Civica's low-cost insulin initiative represents progress toward improving medication access for people with Type 1 diabetes
If you're experiencing issues with your continuous glucose monitor, customer service lines are available to help with troubleshooting and replacements

A Year of Progress in Type 1 Diabetes Treatment

The Type 1 diabetes community is reflecting on significant advances made during 2025. Milestones in cell therapy development and disease-modifying treatments suggest new avenues for managing and potentially altering the course of Type 1 diabetes. While research in these areas continues to evolve, the progress represents the cumulative work of researchers, advocates, and funding mechanisms dedicated to improving outcomes for people living with T1D.

Federal Funding at a Critical Juncture

The Special Diabetes Program (SDP), established in 1997, has historically enjoyed bipartisan congressional support and has been instrumental in funding research breakthroughs and care improvements across the Type 1 diabetes community. That funding is set to expire on January 30, 2026—just weeks away. Advocates are urging members of the community to support long-term renewal of this program to maintain momentum in research and clinical advances.

Expanding Access to Affordable Insulin

Among 2025's developments was Civica's initiative to provide low-cost insulin, addressing a persistent barrier to care for many people with Type 1 diabetes. Combined with research breakthroughs and advocacy efforts, improvements in medication affordability represent a multifaceted approach to better supporting the T1D community.

Support for Continuous Glucose Monitor Users

Many people using continuous glucose monitors (CGMs) occasionally encounter technical issues. Breakthrough T1D has compiled customer service contact information for each CGM manufacturer. If you experience problems with your device, reaching out to the company's customer support team can help you troubleshoot issues, request replacement sensors, and access other assistance.

Connect With Your Local T1D Community

Throughout Northern California, local Breakthrough T1D chapters are hosting in-person and virtual gatherings for people with Type 1 diabetes and their families. Whether you're looking for peer support, outdoor activities, or informal conversations, these events offer opportunities to connect with others navigating life with T1D. Check with your local chapter for dates, times, and registration information.

Evidence label

Origin: Northern California Chapters (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.